Q32 Bio Resets As A Public Company With Two Mid-Stage Assets
Executive Summary
The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.
You may also be interested in...
Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent
Amgen agreed not to include Horizon’s Tepezza and Krystexxa in rebate bundling deals with payers, among other terms, so the FTC would clear the companies’ merger, giving pharma firms a new consideration in future dealmaking.
Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
EyePoint Hits New Durability Milestone For Wet AMD Treatment
Positive Phase II data in wet AMD showing potential for dosing out to six months could spur partnering interest ahead of Phase III development.